Inherited retinal diseases affect more than 200,000 Americans and millions of individuals worldwide (1) (2) (3) . Dozens of different types of disease are included in this set of diseases, and more than 190 genes have been identified as the cause of one or another form of inherited retinal disease (4, 5) . Retinitis pigmentosa (RP) accounts for approximately one-half of cases. RP itself is highly heterogeneous: mutations in more than 50 genes are known to cause non-syndromic RP and nearly 3100 mutations have been reported in these genes (5, 6) . Syndromic forms of RP are equally heterogeneous: mutations in 12 genes cause Usher syndrome and 17 genes are associated with BardetBiedl syndrome; together these two diseases account for another 1200 pathogenic mutations. In addition to genetic and mutational heterogeneity, different diseases may be caused by mutations in the same gene, symptoms of different diseases may overlap, and there is extensive variation in clinical expression even among individuals sharing the same mutation in the same gene.
Despite the complexity, significant progress has been made in recent years in identifying novel RP genes and in screening patients for pathogenic mutations. This is partly the result of development of high-throughput mapping and sequencing techniques, but is also testimony to the large number of investigators and research groups working in this area. In the past two decades, the number of research groups in the world focused on RP genetics has gone from a handful to dozens. The potential options for treatments have also increased markedly. The purpose of this review is to provide an overview of the current status of RP genes. References are largely chosen for illustration; a more comprehensive list is found in RetNet, http://www.sph.uth.tmc/edu/retnet (5) . Inherited retinopathies as a broad class of diseases are reviewed in other publications (4, 7) . This is a fast-moving field and it is encouraging to note that any review will be out of date sooner rather than later.
Heterogeneity
Retinitis pigmentosa is a progressive, degenerative disease of the retina leading to profound loss of vision or blindness (3) . The clinical hallmarks of RP are night blindness, often starting in adolescence, followed by progressive loss of peripheral vision and subsequent loss of central vision. By midlife, RP patients may retain a few degrees of central vision but in many cases the disease culminates in complete blindness. Findings on retinal examination include 'bone spicule' pigmentary deposits, retinal vessel attenuation, and characteristic changes in electroretinogram (ERG) patterns. At a cellular level, a simplified view of RP is progressive dysfunction and loss of rod photoreceptors, first affecting night vision in the rod-rich mid-peripheral retina, then progressing into the cone-rich central retina, with eventual loss of cones either as a direct result of the disease process or secondary to the death of rods.
Within this broad picture, though, there is considerable variation in age of onset, rate of progression, rod vs cone involvement, involvement of other retinal cells such as RPE, secondary symptoms such as cystic macular edema, and many other features. RP which is present at birth or soon after is often referred to as Leber congenital amaurosis (LCA). RP may occur alone, as non-syndromic RP, without other clinical findings, or as syndromic or systemic RP with other neurosensory disorders, developmental abnormalities, or complex clinical phenotypes. Usher syndrome is RP with congenital or early onset deafness. Bardet-Biedl syndrome (BBS) is RP with kidney disease, obesity, polydactyly and developmental delay. RP may also be secondary to systemic disorders such as mitochondrial diseases or various forms of degenerative cerebellar disease. For simplicity, this review is limited to non-syndromic RP, Usher syndrome and BBS (for one reason, because the diseases overlap). Other syndromic and systemic forms of RP are listed in RetNet (5) .
Retinitis pigmentosa is exceptionally heterogeneous. This includes (i) genetic heterogeneity -many different genes may cause the same disease phenotype; (ii) allelic heterogeneity -there may be many different diseasecausing mutations in each gene; (iii) phenotypic heterogeneity -different mutations in the same gene may cause different diseases; and (iv) clinical heterogeneity -the same mutation in different individuals may produce different clinical consequences, even among members of the same family. The extent of heterogeneity of RP can be confusing to patients and clinicians alike, and is a confounding factor in diagnosis.
The most obvious complications are genetic and allelic. Currently, mutations in 56 genes are known to cause non-syndromic RP (Table 1) . Twelve genes account for Usher syndrome and 17 account for BBS (Tables 2 and 3 ). If genes for LCA and for other syndromic or systemic forms of RP are included, at least 100 'RP-related' genes are known. Allelic or mutational heterogeneity is equally striking. Counting all the genes known to cause non-syndromic RP, at nearly 3100 disease-causing mutations are reported in mutation databases (Table 1) . Discounting overlaps with non-syndromic RP, genes causing Usher syndrome and BBS account for at least another 1200 mutations (Tables 2 and 3) .
Although some of the publically reported mutations may, later, turn out to be non-pathogenic, this is still a significant underestimate because many novel mutations are listed in private databases and are not yet in the public domain. Among other concerns, there is need for more systematic collection of mutation phenotype-genotype information for inherited retinal diseases, a need addressed, for example, by the Leiden Open Variation Database (8) .
Equally confusing is the overlap between disease types, disease names, and clinical consequences. First, different mutations in the same gene may cause distinctly different conditions. For example, even though most rhodopsin mutations cause autosomal-dominant RP and most RPE65 mutations cause recessive LCA, some rhodopsin mutations may be recessive acting and some RPE65 mutations may be dominant acting (9) (10) (11) (12) (13) . Usher syndrome mutations are recessive and cause both deafness and RP, but mutations in two Usher genes, CLRN1 and USH2A, may cause recessive RP only (14, 15) .
For non-syndromic RP, mutations in 23 genes are known to cause autosomal-dominant RP, 36 genes cause recessive RP, and 3 genes cause X-linked RP (5) . However, Table 1 shows that several of these diseases overlap with each other and Tables 1-3 show that many genes cause multiple diseases. In some cases the 'secondary' disease is rare (e.g. recessive rhodopsin or dominant RPE65 mutations), but in some cases it is common (e.g. recessive RP and USH2A). Generally, there is no simple mapping between gene and disease in most cases.
Finally, even identical mutations within the same gene may produce different clinical findings. Variation between individuals in age of onset or rate of progression is not unexpected, but, for example, mutations in PRPF31 are non-penetrant in some family members, (16, 17) and mutations in PRPH2 (RDS) produce a wide range of macular, peripheral or pan-retinal symptoms (18, 19) . One consequence is that members of the same family, seen by different clinicians, may have diagnoses that are consistent with findings in the individual but inconsistent with the family. Overall, there is considerable overlap between diseases caused by RP genes even though different names are given to specific types of disease. This is well illustrated by the overlapping disease nomenclature proposed by Berger et al. for inherited retinal diseases (4) .
Fortunately, molecular techniques allow identification of the underlying gene and mutation or mutations in many cases, adding a molecular diagnosis to the clinical diagnosis. Nevertheless, in some cases this leads to (6) . References are in RetNet. Some genes appear in more than one table so the sum total of distinct genes in the tables, 82, is less than the sum of the three tables together. (6) . References are in RetNet. Some genes appear in more than one table so the sum total of distinct genes in the tables, 82, is less than the sum of the three tables together.
apparent contradictions that require further analysis to resolve.
Technical approaches
The standard techniques for gene discovery and mutation detection -linkage mapping and DNA sequencing -have been used for many years. However, development of high-density and high-throughput techniques in the past 10 years has increased the power of these methods by orders of magnitude.
For linkage mapping, high-density SNP (singlenucleotide polymorphism) arrays, such as the Affymetrix 6.0 SNP/CNV array, (20) allow linkage testing against nearly 1 million genetic markers. For practical purposes, these are often collapsed to around 10,000 most-informative markers, with known relationships to contiguous markers. However, even with smaller marker sets, there is a serious issue of the large number of independent tests (multiple comparisons) leading to apparent linkage 'hits' by chance alone. Fortunately, there are many more, highly-variable genetic (6) . References are in RetNet. Some genes appear in more than one table so the sum total of distinct genes in the tables, 82, is less than the sum of the three tables together.
markers in the human genome that can be used to refine linkage mapping (9) . Several RP genes have first been localized by linkage mapping in recent years (21) (22) (23) (24) (25) .
One consequence of availability of dense SNP marker sets is that it is possible to identify regions on homologous chromosomes that are identical-bydescent, that is, regions on a matching pair of chromosomes that derive from a single chromosome in a relatively recent ancestor. This identifies the chromosomal location of identical recessive mutations in families with consanguinity or recent within-family matings. This approach to mapping recessive genes is called homozygosity mapping or autozygosity mapping (26) . It has been very productive in identifying RP genes in inbred families and in ethnic populations where inbreeding is common (27) (28) (29) (30) (31) . Surprisingly, even in families without evidence of consanguinity, recessive RP mutations are more often identical-by-descent than expected, thus expanding the utility of homozygosity mapping (26) .
Methods for detecting mutations at a DNA sequence level include Sanger sequencing, still called the gold standard of sequencing, array-based detection of specific mutations (e.g. APEX, 'array-primer extension' (32-34)), ultra-high-throughput sequencing and others. Of these, the major advance in recent years in finding RP genes is application of ultra-high-throughput sequencing, generally referred to as next-generation sequencing (NGS) (35) . Conventional Sanger sequencing is usually done using semiautomated, multilane capillary electrophoresis (itself a major improvement over earlier methods). In contrast, NGS does millions of sequencing runs in parallel on micron-sized beads or in comparable micro-wells, completing up to a billion base-pair reads per run. That is, NGS sequencing is at least 1000 times faster than conventional sequencing, and much less expensive per sequence.
There are several NGS methods and numerous distinct applications (36, 37) . What most methods have in common is short-read, shot-gun sequencing: DNA is first fragmented into short sequences, read lengths are in the range of 100 to 200 base pairs, and computational methods are used to 'reassemble' the short reads into larger constructs. This allows highly accurate, extremely rapid sequencing of large regions of the human genome, but certain features of human DNA, such as deletions and rearrangements, expanded repeats, and haplotypes, are not accessible to NGS without additional steps. Also, because of the sheer volume of data produced by NGS, dedicated bioinformatic resources are required to fully utilize the results.
Despite these limitations, NGS has been exceptionally productive in gene discovery and mutation detection for RP. Broadly, there are three NGS strategies: whole-exome NGS, whole-genome NGS and targetedcapture NGS. Whole-exome NGS involves capture of all protein-coding regions, that is, all exons, constituting about 1.5% of the human genome, followed by NGS. By definition this technique is limited to finding mutations in coding regions only, but nonetheless it has led to identification of several RP genes and novel mutations (9, 38, 39) . Whole-genome NGS covers nearly all the human genome (about 98%), and avoids potential artifacts introduced by exon capture, but is not yet in routine use for gene discovery. The principal limitations are sequencing costs, and management and analysis of the resulting massive data sets. However, it is likely that whole-genome sequencing will become routine in the near future, especially with development of 'third generation' technologies (40) .
Targeted capture, the third NGS strategy, limits testing to exons of known disease-causing genes (41) -in the case of retinal diseases, for example, testing only the 190-plus genes in RetNet (5). The disadvantage, of course, is that no new genes can be identified. The advantages are that the analysis 'space' is much smaller, more is known, a priori , about each gene, and costs are much lower. Thus this is currently an optimal approach to mutation screening for RP, with many applications (42) (43) (44) (45) (46) (47) .
Finally, some mutations are not easily detected by conventional sequencing or NGS, particularly large deletions and rearrangements. Some deletions can be detected by SNP arrays, and the Affymetrix 6.0 SNP/CNV arrays includes copy-number probes (CNVs) for deletion detection (20) . PCR-amplification based methods, such as MLPA or qPCR, can detect much smaller deletions. This is a significant issue as nearly 3% of cases of autosomal-dominant RP are caused by deletions in PRPF31 not detectable by sequencing (17, 48) . Similar deletions and rearrangements are found in ABCA4, a common cause of recessive RP, and in RPGR, the principal cause of X-linked RP (49) . However, X-linked deletions are easily detected in hemizygous males, and the principal problem in sequencing RPGR is the repetitive nature of ORF15.
Current status of gene discovery and mutation detection
Identification of novel genes causing inherited retinal diseases, including RP, has progressed at a steady, linear rate for nearly 20 years (Fig. 1) . Although the tools for gene discovery are much more powerful, the steady rate in recent years suggests that, in general, each new gene is rarer than preceding genes and thus more difficult to detect. Whole-genome NGS may accelerate gene discovery, but it is possible that the remaining, unknown RP genes are very rare. However, there is no meaningful way to predict the remaining number of RP genes.
The meaningful questions in this context are (i) in what fraction of RP patients can disease-causing mutations be detected today, and (ii) when will it be possible to find mutations in nearly all patients, say, at least 95%? The answer to the first question depends on the technology used and the type of RP. Combining results from conventional Sanger sequencing and targeted-capture NGS, using rough estimates, it is possible to detect the underlying pathogenic mutation or mutations in 20-30% of autosomal recessive RP cases, 60-70% of autosomal-dominant cases, 80-85% of X-linked cases, and more than 85% of Usher and BBS cases (44, 50) [and S.P. Daiger, unpublished data] .
Simplex (isolated) RP cases are more complicated. Traditionally, simplex RP cases are predicted to be recessive, with unaffected carrier parents. This is true in many cases, but there are exceptions. At least 15% of males with RP and no other affected family members have mutations in the X-linked genes RPGR or RP2 (51) . De novo autosomal-dominant mutations account for at least 1-2% of simplex cases (45, 52) . Targeted NGS identifies mutations in 19-36% of simplex RP cases, but confirming pathogenicity in these cases is problematic (44) (45) (46) (47) . A further complication is that the carrier frequency for all inherited retinal disease mutations in unaffected individuals may exceed 20% (53) . That is, each mutation is extremely rare, but there are so many genes and so many mutations, that in aggregate they are common.
Prediction is risky, but given rapid advances in DNA sequencing methods, and continued identification of new RP genes, it is reasonable to expect that within 5 years it will be possible to detect the diseasecausing gene and mutation or mutations in 95% of patients. This is assuming that most of the remaining cases are monogenic, that is, caused by a single gene in each individual. Since digenic forms of RP and triallelic forms of BBS are already known, polygenic inheritance of retinal diseases cannot be discounted (54, 55) .
Finally, genetic diagnosis of RP may change the family diagnosis or raise questions about the relationship between genotype and phenotype. For example, at least 8% of families with a provisional diagnosis of autosomal-dominant RP actually have mutations in X-linked RP genes (56) . Mutations in genes commonly associated with Usher syndrome or BBS may cause non-syndromic RP (14, 15, 57) . Other examples arise from targeted-capture NGS. This can be confusing for the patient and requires thoughtful explanation and counseling. In some cases, it may require redefining the family's disease. Reconciling the clinical phenotype, family history and genetic findings is a critical, new step in the diagnosis of inherited retinal diseases.
